Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion

被引：2
|
作者：
Delaye, Matthieu [1 ,2 ]
Rodrigues, Manuel [3 ,4 ]
机构：
[1] Hop Tenon, Serv Oncol Med & Therapie Cellulaire, 4 Rue Chine, F-75020 Paris, France
[2] Assoc Enseignement & Rech Internes Oncol AERIO, 149 Ave Maine, F-75014 Paris, France
[3] PSL Res Univ, Inst Curie, Dept Oncol Med, 26 Rue Ulm, F-75005 Paris, France
[4] PSL Res Univ, Inst Curie, INSERM, U830, 26 Rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2020年 / 107卷 / 11期
关键词：
POSITIVE SOLID TUMORS;
D O I：
10.1016/j.bulcan.2020.09.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1085 / +
页数：2
相关论文
共 50 条
  • [1] PARAMETRIC SURVIVAL EXTRAPOLATIONS OF LAROTRECTINIB AND ENTRECTINIB FOR NTRK FUSION CANCERS
    Sullivan, S.
    Suh, K.
    Williamson, T.
    Carlson, J. J.
    VALUE IN HEALTH, 2022, 25 (12) : S15 - S15
  • [2] Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers
    Suh, Kangho
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1011 - 1019
  • [3] Larotrectinib in NTRK fusion tumours
    Costa, Marcia
    LANCET ONCOLOGY, 2021, 22 (01): : 18 - 18
  • [4] Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
    Garcia-Foncillas, J.
    Bokemeyer, C.
    Italiano, A.
    Keating, K.
    Paracha, N.
    Fellous, M.
    Marian, M.
    Fillbrunn, M.
    Gao, W.
    Ayyagari, R.
    Lassen, U. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S401 - S401
  • [5] FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors
    Marcus, Leigh
    Donoghue, Martha
    Aungst, Stephanie
    Myers, Claire E.
    Helms, Whitney S.
    Shen, Guoxiang
    Zhao, Hong
    Stephens, Olen
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 928 - 932
  • [6] Entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis
    Garrido-Laguna, I.
    Lonardi, S.
    Bazhenova, L.
    Peeters, M.
    Longo, F.
    Sigal, D.
    Conkling, P.
    Duffaud, F.
    Klingbiel, D.
    Bordogna, W.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S370 - S371
  • [7] Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
    Garcia-Foncillas, Jesus
    Bokemeyer, Carsten
    Italiano, Antoine
    Keating, Karen
    Paracha, Noman
    Fellous, Marc
    Marian, Marisca
    Fillbrunn, Mirko
    Gao, Wei
    Ayyagari, Rajeev
    Lassen, Ulrik
    CANCERS, 2022, 14 (07)
  • [8] Larotrectinib: New Tyrosine Receptor Kinase Inhibitor Approval for NTRK Fusion Tumors independent of Histology
    Eiden, Petra
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (11) : 619 - 619
  • [9] Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer
    Carlson, Josh J.
    Italiano, Antoine
    Brose, Marcia S.
    Federman, Noah
    Lassen, Ulrik
    Kummar, Shivaani
    Sullivan, Sean D.
    AMERICAN JOURNAL OF MANAGED CARE, 2022, 28 (02): : S26 - S32
  • [10] COST-EFFECTIVENESS ANALYSIS OF LAROTRECTINIB AND ENTRECTINIB FOR ADULT PATIENTS WITH NTRK GENE FUSION-POSITIVE BREAST CANCER
    Dheer, P.
    Kamerikar, V
    Fleming, M.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
12345